Reduce Costs When Prescribing NSAIDs
Guidance for prescribers to reduce medication costs by choosing lower-cost non-steroidal anti-inflammatory drugs (NSAIDs) and counseling patients about switching when medically appropriate; intended for clinicians prescribing NSAIDs for EmblemHealth members.
No material clinical or coverage changes in this revision.
Cost-Reduction Guidance for NSAID Prescribing
Cost-reduction guidance
Prescribing guidance to reduce cost of NSAID therapy for members.
Listed NSAIDs and Formulations
| Diclofenac (topical) | Diclofenac sodium topical solution/gel/pump; strengths: 1.5%, 2%, 3% |
| Diclofenac (oral) | Diclofenac potassium tablet/capsule/powder packet; strengths: 25 mg, 50 mg |
| Meloxicam | Meloxicam tablet/capsule; strengths: 5 mg, 15 mg |
| Naproxen | Naproxen immediate- and delayed-release tablets and suspension; strengths: 125 mg/5 mL, 500 mg |
| Naproxen + Esomeprazole | Combination product (e.g., VIMOVO); naproxen 375 mg or 500 mg + esomeprazole 20 mg |
| Ibuprofen + Famotidine | Combination product (e.g., DUEXIS); ibuprofen 800 mg + famotidine 20 mg (formulations noted as 80Omg/20mg in source likely 800 mg) |
Prescribing Actions and Patient Counseling
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.